68Ga-DOTATATE PET

temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours

George Barberio Coura-Filho, Ana A.F.O. Hoff, Paulo S. Duarte, Carlos A. Buchpiguel, Nils Anders Mauritz Josefsson, Robert Hobbs, George Sgouros, Marcelo T. Sapienza

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Higher affinity of Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. METHODS: Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. RESULTS: Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. CONCLUSION: Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.

Original languageEnglish (US)
Pages (from-to)920-926
Number of pages7
JournalNuclear medicine communications
Volume40
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Neuroendocrine Tumors
Reference Values
Somatostatin
Neoplasms
Somatostatin Receptors
Liver
Intravenous Injections
Tomography
Kidney
68Ga-DOTATATE

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

68Ga-DOTATATE PET : temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. / Coura-Filho, George Barberio; Hoff, Ana A.F.O.; Duarte, Paulo S.; Buchpiguel, Carlos A.; Josefsson, Nils Anders Mauritz; Hobbs, Robert; Sgouros, George; Sapienza, Marcelo T.

In: Nuclear medicine communications, Vol. 40, No. 9, 01.09.2019, p. 920-926.

Research output: Contribution to journalArticle

Coura-Filho, George Barberio ; Hoff, Ana A.F.O. ; Duarte, Paulo S. ; Buchpiguel, Carlos A. ; Josefsson, Nils Anders Mauritz ; Hobbs, Robert ; Sgouros, George ; Sapienza, Marcelo T. / 68Ga-DOTATATE PET : temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. In: Nuclear medicine communications. 2019 ; Vol. 40, No. 9. pp. 920-926.
@article{faf579d7d52b46d7af8f36e3031dd09f,
title = "68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours",
abstract = "OBJECTIVES: Higher affinity of Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. METHODS: Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. RESULTS: Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. CONCLUSION: Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.",
author = "Coura-Filho, {George Barberio} and Hoff, {Ana A.F.O.} and Duarte, {Paulo S.} and Buchpiguel, {Carlos A.} and Josefsson, {Nils Anders Mauritz} and Robert Hobbs and George Sgouros and Sapienza, {Marcelo T.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/MNM.0000000000001048",
language = "English (US)",
volume = "40",
pages = "920--926",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - 68Ga-DOTATATE PET

T2 - temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours

AU - Coura-Filho, George Barberio

AU - Hoff, Ana A.F.O.

AU - Duarte, Paulo S.

AU - Buchpiguel, Carlos A.

AU - Josefsson, Nils Anders Mauritz

AU - Hobbs, Robert

AU - Sgouros, George

AU - Sapienza, Marcelo T.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - OBJECTIVES: Higher affinity of Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. METHODS: Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. RESULTS: Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. CONCLUSION: Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.

AB - OBJECTIVES: Higher affinity of Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs). This study aimed to evaluate the maximum standardized uptake value (SUVmax) variation in sequential somatostatin analogs-PET in NET patients and identify optimal tumour detection and characterization imaging time. METHODS: Patients with histological or biochemical NET diagnosis performed two to three PET/computed tomography (CT) scans after intravenous injection of Ga-DOTATATE: Early PET [EarlyPET: <15 minutes postinjection (p.i.)], diagnostic PET (DiagPET: 45-90 minutes p.i.) and delayed PET (DelayPE: 90-240 minutes p.i.). Up to five tumour sites and normal tissues had SUVmax determined. Time-SUVmax curves were created for the target lesions and normal organs. Ratios between tumour and liver SUVmax (SUVTU/Liver) and tumour/blood pool (SUVTU/BP) were also calculated. RESULTS: Twenty-nine patients were included, 16 female, mean age of 46.5 ± 14.3 years. Average administered activity was 129.5 ± 29.6 MBq. Kidneys SUVmax was higher in EarlyPET compared with DiagPET (P = 0.04) and DelayPET showed higher SUVmax compared with DiagPET for normal liver, pancreas and kidneys (P = 0.02). No differences were noted between EarlyPET, DiagPET and DelayPET in tumour SUVmax (P > 0.05). SUVTU/Liver and SUVTU/BP did not change between EarlyPET and DiagPET, with a slight decrease in DelayPET. CONCLUSION: Stability in tumour SUVmax values measured at different intervals independently of tumour location, as also in normal tissues as kidneys and liver suggest that a more flexible imaging protocol may be adopted.

UR - http://www.scopus.com/inward/record.url?scp=85071351195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071351195&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000001048

DO - 10.1097/MNM.0000000000001048

M3 - Article

VL - 40

SP - 920

EP - 926

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 9

ER -